It’s tough to say because the methodology and reporting was somewhat different in the 1999 study between the supplements and the foods. There were three trials per person with 24-h urine collection for the supplements and one trial per person with 8-h urine collection for the foods. They reported that ~30% of a 15 mmol supplement was converted to TMA+TMAO over 24 h. If excretion in urine is constant over 24 h, this yields 1500 umol/8 h, which is comparable to some of the lighter seafoods. However, the dose is very large (~ g, about 13 servings of steak).
After 8 weeks, mean blood pressure remained unchanged from baseline in controls (systolic/diastolic: 133 ± 5/77 ± 6 vs 135 ± 11/80 ± 7 mmHg) and the low-dose group (136 ± 7/77 ± 7 vs 133 ± 10/76 ± 7), but had significantly decreased for the high dose group (137 ± 10/80 ± 10 vs 126 ± 9/76 ± 6). Cholesterol levels decreased for all treatments with significant dose-dependent within-pair differences for LDL-cholesterol. None of the other parameters showed significant changes or consistent trends. Concluding, the study confirmed the antihypertensive and cholesterol-lowering action of EFLA®943 in humans.